Schering Temodar Data Show Long-Term Survival Rates Improve Fourfold Over Radiation Alone
This article was originally published in The Pink Sheet Daily
Survival benefit of Temodar and radiation in glioblastoma patients was 12.1 percent in year four versus 3 percent with radiation alone.
You may also be interested in...
Approval of temozolomide was based on a Phase III trial that demonstrated a statistically significant survival benefit in combination with radiotherapy versus radiotherapy alone. Temodar also received full approval for its original indication of anaplastic astrocytoma.
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.